AMRA-MEDICAL
29.8.2024 15:56:33 CEST | Business Wire | Press release
AMRA Medical, a leading force in the development of MRI-based body composition analyses and biomarkers, is pleased to announce their EU Medical Device Regulation (MDR) certificate for the cutting-edge AMRA® Profiler 4 body composition analysis device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829196647/en/
AMRA® Profiler 4 provides rapid and precise body composition measurements in relation to normative data, contextualizing insights at the individual patient level, with high accuracy. (Graphic: Business Wire)
The 2017/745 (EU) MDR outlines the European regulations for medical devices and contains requirements, e.g., on the production, distribution, evaluation, and surveillance of medical devices. Manufacturers of medical devices must ensure compliance to MDR prior to bringing a medical device to the EU market. These requirements ensure that a medical device placed on the European market is both safe and effective for use by patients and providers.
The certificate comes as a successor to AMRA® Profiler 4’s 510(k) clearance by the US Food and Drug Administration (FDA), comfortably meeting the high standards for both EU and US markets in the push for increased use of AMRA’s cutting-edge body composition analysis methodologies in the clinic. Now that AMRA® Profiler 4 is CE marked, the device’s conformity with European MDR General Safety and Performance Requirements is clear. AMRA consistently demonstrates robust scientific methods and maturity in product development as they continue to take key steps in clinically translating their exciting MRI-based technologies.
AMRA® Profiler 4 provides clinicians with fat distribution, e.g., liver fat, and muscle composition biomarkers that comprise a detailed body composition profile to assist in diagnosis. Implemented right at the clinic, AMRA® Profiler 4 provides rapid and precise body composition measurements in relation to normative data, contextualizing insights at the individual patient level, with high accuracy. The AMRA biomarkers underlying this technology have proven to be useful in metabolic disease research efforts using the AMRA® Researcher service, and AMRA® Profiler 4’s recent MDR certification brings these powerful and unique biomarkers one step closer to patients everywhere.
Currently, AMRA® Profiler 4 is fully available through AMRA’s service provision in the UK, US, and Canada - with plans to roll out the product in the EU in the future following this MDR certificate milestone. If you or your organization are based in the currently cleared markets and would like to know more about bringing AMRA® Profiler 4 to your clinic, please contact info@amramedical.com.
You can learn how AMRA is using MRI-based fat distribution and muscle composition assessments to advance both research and clinical care by visiting our website, or get in touch with our knowledgeable scientists at info@amramedical.com to learn more about what AMRA can do for your trials, or for your patients.
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering services via their innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in fat distribution and muscle composition assessments in disease research and precision medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829196647/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
rhode Continues Its Global Retail Expansion Into Sephora Europe30.4.2026 18:00:00 CEST | Press release
This expansion into Sephora Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand rhode, the beauty brand founded by Hailey Rhode Bieber, will be available at Sephora online and in most stores across Europe beginning this September, following its 2025 rollout with Sephora in the U.S., Canada, and the U.K. This expansion into Sephora Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430569580/en/ rhode continues its global retail expansion into Sephora Europe. rhode’s collection of high-performance, skin-focused products saw strong performance in Sephora U.S. and Canada as the biggest brand launch in the retailer’s history in North America. When launched in November 2025 in the U.K., rhode was also the largest brand launch in Sephora U.K.’s history. “I’m so excited
ABS Acquires RMC Global to Strengthen Cyber, Risk and Resilience Capabilities30.4.2026 17:46:00 CEST | Press release
Acquisition to Deliver Stronger, More Integrated Solutions for Clients ABS, through its affiliate ABSG Consulting Inc. (ABS Consulting), has today announced the acquisition of RMC Global (RMC), a leading provider of industrial cybersecurity, risk management and resiliency solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430164690/en/ (L to R): Vince Kuchar, President, RMC Global, and David Wechsler, President and CEO, ABS Group The acquisition strengthens ABS Consulting’s capabilities and market position, bringing together two organizations with complementary expertise, shared values and a common mission. Combining RMC’s capabilities with ABS Consulting’s scale, technical depth and global resources, unlocks more integrated solutions for clients operating in increasingly complex risk environments. ABS Chairman and CEO John McDonald said: “Clients are facing increasing operational risk, cyber threats, and regulator
Brightfin Unveils AI-Native Platform for IT Financial Management30.4.2026 17:00:00 CEST | Press release
Brightfin clients drive their businesses forward with the first AI Native Cost Optimization Platform Brightfin, the only ITFM and Technology Expense Management solution built natively on ServiceNow, today announced an AI-Native architecture that fundamentally improves how organizations manage IT spend. Rather than bolting AI onto legacy systems, Brightfin has engineered intelligence from the ground up - starting with the data, building contextual awareness on top of it, and delivering AI agents that speak the language of IT finance. Brightfin’s unified budget-to-billing data model creates a stable, governed foundation that connects contracts, invoices, inventory, and budgets into a single source of truth - something no external ITFM tool or native platform module can replicate. This is a structured financial backbone purpose-built for enterprise IT spend, and it’s what makes everything above it possible. A context-aware, AI-Native, intelligence layer understands relationships across th
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 15:22:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et
Experian Announces Agent Trust to Power Trusted AI Driven Commerce30.4.2026 15:00:00 CEST | Press release
First-of-its-kind human-to-agent binding service for secure AI-driven commerce, developed with a growing ecosystem of agentic commerce collaborators, including Visa, Cloudflare and Skyfire Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430719198/en/ Experian Announces Agent Trust to Power Trusted AI Driven Commerce. As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust addresses this challenge through a new “Kn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom